Lataa...
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
Eribulin mesylate, a synthetic derivative of the anti-mitotic agent halichondrin B, has a unique tubulin-based mechanism of action that is distinct from other anti-microtubule agents including taxanes and vinca alkaloids. Consistent with this unique activity, eribulin has shown clinical efficacy in...
Tallennettuna:
| Julkaisussa: | Breast Cancer (Dove Med Press) |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7917473/ https://ncbi.nlm.nih.gov/pubmed/33658845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S231298 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|